Abstract: A composition, medicament or use, comprising or consisting of botulinum toxin type A2 and a surfactant, having one or more or all of the characteristics selected from the group consisting of; (a) a much longer duration of action; (b) a much faster rate of onset of muscular paralysis; (c) a significantly greater intramuscular safety margin; (d) a selective action on inhibition of skeletal muscle contraction; (e) a selective action on inhibition of pain-related (nociceptive) nerve cell function: Wherein each characteristic is determined comparative to the same characteristic effect of botulinum toxin type A1.

Abstract: A composition, medicament or use, comprising or consisting of botulinum toxin type A2 and a surfactant, having one or more or all of the characteristics selected from the group consisting of; (a) a much longer duration of action; (b) a much faster rate of onset of muscular paralysis; (c) a significantly greater intramuscular safety margin; (d) a selective action on inhibition of smooth muscle contraction; (e) a selective action on inhibition of pain-related (nociceptive) nerve cell function: Wherein each characteristic is determined comparative to the same characteristic effect of botulinum toxin type A1.

Abstract: A composition, medicament or use, comprising or consisting of botulinum toxin type A2 and a surfactant, having one or more or all of the characteristics select from the group consisting of; (a) a much longer duration of action; (b) a much faster rate of onset of muscular paralysis; (c) a significantly greater intramuscular safety margin; (d) a selective action on inhibition of skeletal muscle contraction; (e) a selective action on inhibition of pain-related (nociceptive) nerve cell function: Wherein each characteristic is determined comparative to the same characteristic effect of botulinum toxin type A1.

Abstract: The present invention relates to the use of CD36 (“CD36”) receptor as a heat shock protein receptor, cells that express CD36 bound to an HSP, and antibodies and other molecules that bind CD36-HSP complex. The invention also relates to screening assays to identify compounds that interact with CD36, and modulate the interaction of CD36 with its ligand, such as HSPs, and methods for using compositions comprising CD36-receptor sequences for the diagnosis and treatment of immune disorders, proliferative disorders, and infectious diseases.